Results from First-in-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease

被引：0
|
作者：
Greenberg, Barry
Eshraghian, Emily
Battiprolu, Pavan
Ricks, David
Yarabe, Paul
Schwartz, Jonathan
Patel, Kinnari
Shah, Guarav
Trevejo, Jose
机构：
来源：
CIRCULATION | 2021年 / 144卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A10727
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Initial safety and feasibility results from a first-in-human clinical trial evaluating a novel magnetic hyperthermia approach for the treatment of metastatic solid tumors
    Kraus, Sarah
    Tal, Cheri
    Shalev, Boaz
    Eltanani, Moshe
    Rukenstein, Pazit
    Arbib, Shir
    Eck, Michal
    Khandadash, Raz
    Atar, Shaul
    Cyjon, Arnoldo
    Shalev, Ofer
    CANCER RESEARCH, 2023, 83 (08)
  • [32] Preliminary Results from the Phase 1/2 GuardOne Trial: A First-in-Human Study of Ex Vivo Lentiviral Gene Therapy (AVR-RD-02) in People with Gaucher Disease Type 1
    Jacobsen, L. K.
    Trame, M. N.
    Golipour, A.
    Pfeifer, R.
    Khan, A.
    Mason, C.
    MOLECULAR THERAPY, 2021, 29 (04) : 340 - 340
  • [33] Interim Review of Safety, Tolerability, and Efficacy From a First-In-Human Phase 1/2a Clinical Study of ICM-203, an Intra-Articular, AAV Gene Therapy for Osteoarthritis
    Heald, Alison E.
    Solomon, Bogdan
    Page, Richard
    Ahn, Yoenhee
    Yum, Young Na
    Myung, Jayhyuk
    Collins, Jamie E.
    Guermazi, Ali
    Kim, Dae-Won
    MOLECULAR THERAPY, 2024, 32 (04) : 80 - 80
  • [34] INTERIM DATA FROM THE FIRST-IN-HUMAN PHASE 1/2A TRIAL OF ICM-203, AN INTRA-ARTICULAR, AAV GENE THERAPY FOR OSTEOARTHRITIS - SAFETY, TOLERABILITY, AND PRELIMINARY EVALUATION OF CLINICAL ACTIVITY IN LOW DOSE COHORT
    Heald, Alison E.
    Solomon, Lucien B.
    Page, Richard
    Ahn, Yoenhee
    Yum, Young Na
    Myung, Jayhyuk
    Collins, Jamie E.
    Guermazi, Ali
    Kim, Dae-Won
    OSTEOARTHRITIS AND CARTILAGE, 2024, 32 : S589 - S589
  • [35] Preliminary results from a phase 1-2 gene therapy study of ATA-100, AAV9 vector encoding FKRP, in patients with limb girdle muscular dystrophy R9
    Olivier, S.
    Richard, I.
    Stojkovic, T.
    Straub, V.
    Preisler, N.
    Zanfongnon, R.
    Buscara, L.
    Genries-Ferrand, S.
    Vissing, J.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [36] A First-in-Human Phase 1 Clinical Gene Therapy Trial for the Treatment of Heart Failure Using a Novel Re-Engineered Adeno-Associated Vector
    Henry, Timothy
    Chung, Eugene
    Traverse, Jay
    Reynolds, Kristi
    Alvisi, Monica
    Ervin, Leigh
    Krupa, Shiva
    O'Callaghan, Michael
    Sadek, Hesham
    Tretiakova, Anna
    High, Katherine
    Jiang, Canwen
    Mikhail, Sheila
    Samulski, Richard Jude
    Kranias, Evangelia
    Hajjar, Roger
    MOLECULAR THERAPY, 2022, 30 (04) : 14 - 15
  • [37] Systemic AAV9 Human Propionyl-CoA Carboxylase, Alpha Subunit (AAV9-hPCCA) Gene Therapy Provides Direct and Sustained Therapeutic Benefits in the Treatment of Propionic Acidemia: From Animal Model to Orphan Drug Designation (ODD)
    Li, Lina
    Choi, Eun-Young
    Smith, Stephanie
    Wagner, Erik
    Chen, Catherine
    Xu, Xin
    Ottinger, Elizabeth
    Brooks, Philip J.
    Chandler, Randy J.
    Venditti, Charles P.
    MOLECULAR THERAPY, 2022, 30 (04) : 473 - 473
  • [38] A first-in-human phase 1 clinical gene therapy trial for the treatment of heart failure using a novel rationally designed cardiotropic adeno-associated vector
    Alvisi, Monica
    Henry, Timothy
    Chung, Eugene
    Traverse, Jay
    Ervin, Leigh
    Krupa, Shiva
    Sadek, Hesham
    Jiang, Canwen
    Mikhail, Sheila
    Haghighi, Kobra
    Kranias, Evangelia
    Samulski, Jude
    Tretalova, Anna
    Hajjar, Roger
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2022, 173 : S113 - S113
  • [39] CANaspire Trial of Systemic AAV9-mediated Gene Therapy for Canavan Disease: Biomarker, Imaging and Clinical Findings from the Low-dose Cohort
    Laforet, G.
    Fay, A.
    Nagy, A.
    Harmatz, P.
    Mallack, E.
    Burton, C.
    Langer, K.
    Townsend, E.
    Kiefer, M.
    Leiro, B.
    Williams, R.
    Shaywitz, A.
    Bley, A.
    Eichler, F.
    ANNALS OF NEUROLOGY, 2025, 96 : S24 - S25
  • [40] XC001 gene therapy for the treatment of refractory angina: 6-month efficacy and safety from the phase 1/2 first-in-human study (EXACT Trial)
    Stewart, D. J.
    Dittrich, H. C.
    Reinhardt, R. R.
    Rosengart, T. K.
    Crystal, R. G.
    Povsic, T. J.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A44 - A44
12345